ARCHIVES

FDA Approves Gilotrif Tablets in NSCLC, Boehringer Ingelheim’s First Approved Cancer Drug

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

NCI Spent $381.2 Million On PR From 2006 to 2012, Vastly Outspending Other NIH, FDA Units

March 1, 2013

In Brief: Donaldson, Wilson Lead ASTRO; Thomas To Hear Arguments In Cigarette Case; Doll, Peto Honored

November 8, 1991

AE-941 Shark Cartilage Doesn’t Improve Lung Cancer Survival

May 28, 2010

Basic Research Group Seeks $7.9 Billion For NIH, $1.7 For NCI

July 24, 1987

High Radiation Dose Effective Ten Years After Treatment

November 28, 2003

Program Announcement Completes NCI switch To Control Research

April 16, 1982